ByteDance Finalizes Majority U.S.-Owned TikTok Joint Venture to Avert American Ban 
Toyota Recalls 162,000 Tundra Vehicles in U.S. Over Multimedia Display Issue 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
SEC Drops Gemini Enforcement Case After Full Repayment to Earn Investors 
Winter Storm Triggers Widespread Flight Cancellations Across U.S. as Airlines Urge Travelers to Rebook 
FSU Criticizes ANZ Over Suncorp Bank Job Cuts Amid Post-Acquisition Commitments 
Walmart to Cut PhonePe Stake in IPO as Tiger Global and Microsoft Exit 
U.S. Vaccine Policy Shifts Under RFK Jr. Create Uncertainty for Pharma and Investors 
Memory Chip Shortage Drives Higher Gadget Prices and Weakens Global Tech Demand 
Hermès Menswear Marks Historic Transition as Véronique Nichanian Bids Farewell in Paris 
Microsoft Restores Microsoft 365 Services After Widespread Outage 
FCC Chairman Raises Competition Concerns Over Netflix–Warner Bros. Discovery Deal 
FAA Says It Is Not Blocking Boeing 737 MAX 7 and MAX 10 Certification 
Ericsson Plans SEK 25 Billion Shareholder Returns as Margins Improve Despite Flat Network Market 
BitGo IPO Prices Above Range, Raises $212.8M in Landmark Crypto Market Debut 
Valero Makes First Venezuelan Crude Purchase Under New U.S.-Caracas Deal 
CN Energy Group Inc. Stock Slides After Nasdaq Delisting Notice Over Bid Price Rule 
IRVINE, Calif., May 09, 2017 -- Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular” or the “Company”) (NYSE:IMUC). Investors who purchased or otherwise acquired shares between May 1, 2012 and December 11, 2013, inclusive (the “Class Period”), are encouraged to contact the Firm before the June 30, 2017 lead plaintiff motion deadline.
If you purchased ImmunoCellular shares during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang LLP, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at [email protected].
There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may also choose to take no action and remain a passive class member.
According to the Complaint, during the Class Period, ImmunoCellular issued materially false and/or misleading statements and/or failed to disclose: that the Company retained Lidingo Holdings, LLC to publish promotional articles designed to unlawfully promote the Company; and that the market was led to believe that the Company’s clinical studies for its product candidate ICT-107 were going well and the share price was artificially inflated. When this news was announced, ImmunoCellular’s stock price fell materially, which harmed investors according to the Complaint. On April 10, 2017, the SEC announced enforcement actions against numerous individuals and entities, including ImmunoCellular, that engaged in stock promotion schemes.
If you wish to learn more about this lawsuit, or if you have any questions about this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at [email protected].
This press release may constitute Attorney Advertising in some jurisdictions.
Contact Joon M. Khang, Esq. Telephone: 949-419-3834 Facsimile: 949-225-4474 [email protected]
